# colorectal cancer - gpt-5.6-luna

- Benchmark system: raw
- Repeat: 1
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 3630
- Completion tokens: 4974
- Reasoning tokens: 
- Total tokens: 8604
- API requests reported: 
- Elapsed seconds: 93.057
- Final benchmark system: raw; file rank 1/5; original repeat 1; model vendor: OpenAI

---
## 1. Overall biological interpretation

This is a **prognostic**, not disease-versus-normal, analysis; therefore the results identify transcriptomic features associated with colorectal-cancer overall survival rather than genes proven to be differentially expressed in tumors.

The strongest adverse associations include **INHBB, DCBLD2, ITGBL1, NT5E, MSLN, SCARA3, TPM4, ABL2, MIR31HG, and ZEB1-AS1**, with HRs of approximately 1.30–1.43 and FDRs below 0.05. These genes collectively suggest that poor survival is associated with a tumor state involving:

- extracellular-matrix remodeling and motility,
- stromal or mesenchymal features,
- altered cell–cell and cell–matrix signaling,
- possible adenosine-mediated immune suppression,
- and regulatory noncoding-RNA programs.

Conversely, several genes associated with better survival—particularly **CDX1, CDX2, LGALS4, MYO5B, TAPBPL, ATP23, NDUFA9, GLYCTK, CS, MCCC2, and OGDHL**—are compatible with preserved epithelial differentiation, intestinal lineage identity, antigen-presentation capacity, and mitochondrial/metabolic integrity.

The most defensible interpretation is therefore a contrast between a **poor-prognosis, invasive/stromal-associated state** and a **better-prognosis, differentiated and metabolically competent epithelial state**. However, because the dataset is from bulk colorectal tumor tissue and contains no multivariable clinical information, part of this signal may reflect tumor purity, stromal abundance, molecular subtype, disease stage, or treatment exposure rather than tumor-cell-intrinsic mechanisms.

---

## 2. Core biological programs

### Program 1: Extracellular-matrix remodeling, adhesion, and invasive/mesenchymal behavior

**Direction:** Predominantly adverse association with OS.

**Supporting genes:**  
**ITGBL1** HR 1.299; **DCBLD2** HR 1.408; **PTPN14** HR 1.362; **ABL2** HR 1.301; **TPM4** HR 1.364; **SCEL** HR 1.254; **ADAMTS18** HR 1.263; **NIN** HR 1.345; **GJB6** HR 1.290.

**Most appropriate standardized pathways:**  

- GO: **extracellular matrix organization**
- GO: **cell-substrate adhesion**
- GO: **regulation of cell migration**
- Hallmark: **epithelial–mesenchymal transition**, as a hypothesis rather than a demonstrated enrichment result

**Interpretation:**  
The combination of integrin-associated signaling (**ITGBL1**), extracellular-matrix-related proteins (**DCBLD2, ADAMTS18**), cytoskeletal/contractile components (**TPM4**), and signaling or structural regulators (**PTPN14, ABL2, NIN**) is more informative than any individual gene. Together, these features are compatible with altered adhesion, matrix interaction, cytoskeletal remodeling, and invasive tumor behavior.

**Evidence strength:** **Supported hypothesis.**  
Direct evidence comes from the concordant adverse HRs of multiple genes. Ontology and pathway annotations support functional relatedness. Published cancer literature generally supports roles for ITGBL1, ABL-family signaling, and matrix remodeling in invasion or progression, although that external evidence is not independent of the general cancer biology used to construct these annotations.

**Limitations:**  
No direct EMT score, collagen/fibroblast signature, invasion assay, or pathway-enrichment result was supplied. Several genes may also mark fibroblasts, endothelial cells, or other stromal compartments. The interpretation should not be described as proof of EMT or metastasis.

---

### Program 2: TGF-β-family, stromal signaling, and extracellular purinergic/immune modulation

**Direction:** Predominantly adverse, but biologically heterogeneous.

**Supporting genes:**  
**INHBB** HR 1.433; **NT5E/CD73** HR 1.313; **NPR3** HR 1.350; **ITGBL1** HR 1.299; **DCBLD2** HR 1.408; **MSLN** HR 1.313; **SCARA3** HR 1.377.

**Most appropriate standardized pathways:**  

- Reactome: **TGF-beta receptor signaling** or broader **TGF-beta family signaling**, as a hypothesis
- GO: **cellular response to growth factor stimulus**
- GO: **extracellular matrix organization**
- Purine-related interpretation: **adenosine biosynthetic process**, specifically for NT5E, but not as a complete pathway based on this list alone

**Interpretation:**  
**INHBB**, a member of the inhibin/activin/TGF-β superfamily, is the strongest adverse signal in the table. Its co-occurrence with **ITGBL1, DCBLD2, and NT5E** is consistent with a microenvironmental program involving growth-factor signaling, matrix remodeling, and potentially immunosuppressive extracellular adenosine. **MSLN** and **SCARA3** may additionally reflect tumor-cell or stromal states associated with aggressive disease.

**Evidence strength:** **Supported but incomplete hypothesis.**  
The statistical evidence is strong for several individual genes. Pathway annotation and literature support plausible roles for INHBB in TGF-β-family biology and NT5E in extracellular adenosine production. These are not fully independent evidence streams: pathway databases and literature often derive from the same experimental knowledge base.

**Limitations:**  
The table does not contain canonical TGF-β response genes such as a broad SMAD target module, nor does it include multiple adenosine-pathway genes. Thus, a coordinated TGF-β or adenosine program is not established. Bulk-tissue composition is a major alternative explanation, particularly for NT5E and matrix-associated genes.

---

### Program 3: Preserved intestinal epithelial differentiation and absorptive function

**Direction:** Protective association with OS.

**Supporting genes:**  
**CDX2** HR 0.748; **CDX1** HR 0.781; **LGALS4** HR 0.771; **MYO5B** HR 0.748; **LGALS9** HR 0.753; **PRR15L** HR 0.801.

**Most appropriate standardized pathways:**  

- GO: **epithelial cell differentiation**
- GO: **intestinal epithelial cell differentiation**
- GO: **cell–cell adhesion**
- Broad epithelial-lineage or intestinal differentiation signatures

**Interpretation:**  
The concordant protective associations of **CDX1** and **CDX2**—intestinal transcriptional regulators—together with **LGALS4** and **MYO5B**, genes associated with epithelial or intestinal cell function, support a better-prognosis state retaining differentiated colorectal epithelial characteristics. This is more coherent than interpreting CDX1 or CDX2 alone.

The inverse relationship between this module and adverse matrix-associated genes is biologically compatible with a transition from differentiated epithelial identity toward a less differentiated, invasive phenotype. In the current dataset, however, this is a **prognostic association**, not proof that loss of differentiation causes poor survival.

**Evidence strength:** **Supported hypothesis, approaching established association for CDX1/CDX2 as lineage markers.**  
Evidence comes directly from multiple protective HRs, established intestinal biology, and ontology-level functional coherence. External evidence in colorectal cancer generally links retained intestinal differentiation with tumor phenotype and clinical behavior, but the magnitude and independence of this association require validation in the present cohort.

**Limitations:**  
CDX1 and CDX2 expression can reflect tumor subtype and differentiation state rather than an active protective mechanism. LGALS4 and MYO5B may also be sensitive to epithelial content or tumor purity.

---

### Program 4: Mitochondrial and central-carbon metabolic competence

**Direction:** Predominantly protective.

**Supporting genes:**  
**ATP23** HR 0.688; **NDUFA9** HR 0.689; **GLYCTK** HR 0.709; **MCCC2** HR 0.739; **ILVBL** HR 0.725; **CS** HR 0.754; **OGDHL** HR 0.686; **ATP5G1** HR 0.747; **ATP5B** HR 0.748; **COA3** HR 0.744; **TIMM13** HR 0.751.

**Most appropriate standardized pathways:**  

- KEGG: **Oxidative phosphorylation**
- Reactome: **Respiratory electron transport**
- GO: **tricarboxylic acid cycle**
- GO: **mitochondrial respiratory chain complex assembly**

**Interpretation:**  
This is one of the clearest network-level patterns in the table. Multiple genes involved in mitochondrial protein handling, electron transport, ATP synthesis, and intermediary metabolism show HRs below 1. The pattern is compatible with better survival in tumors retaining mitochondrial and oxidative metabolic programs, potentially reflecting better differentiation or a less aggressive metabolic state.

**Evidence strength:** **Supported association.**  
The evidence is based on many concordant protective genes across related mitochondrial functions, not on a single canonical marker. Pathway annotations independently provide strong functional coherence, although expression-based pathway databases can overstate specificity because many mitochondrial genes participate in multiple general cellular processes.

**Limitations:**  
This does not demonstrate increased oxidative phosphorylation activity. It could reflect greater mitochondrial content, epithelial purity, lower necrosis, or differences in tumor cellularity. Functional metabolic assays and independent pathway scores are needed.

---

### Program 5: Noncoding-RNA and transcriptional regulation associated with poor outcome

**Direction:** Predominantly adverse.

**Supporting genes:**  
**MIR31HG** HR 1.309; **ZEB1-AS1** HR 1.372; **NR2F1-AS1** HR 1.314; **LINC00973** HR 1.214; **RUNX1-IT1** HR 1.311; **LOC101928747|RBMX|SNORD61** HR 1.369.

**Most appropriate standardized pathways:**  
No single GO, Reactome, or KEGG pathway can be assigned confidently from these lncRNA and composite probe signals alone. The most appropriate description is a **regulatory noncoding-RNA program associated with aggressive tumor biology**.

**Interpretation:**  
Several lncRNA-related probes independently associate with worse survival. This may reflect transcriptional states linked to proliferation, dedifferentiation, EMT-like behavior, or altered chromatin regulation. **ZEB1-AS1** is biologically compatible with regulation of epithelial–mesenchymal plasticity, while **MIR31HG** has been associated in cancer studies with aggressive transcriptional states. These relationships remain gene-specific and should not be generalized to all lncRNAs in the list.

**Evidence strength:** **Exploratory to supported hypothesis.**  
The direct evidence is the repeated adverse prognostic direction. External literature can provide plausible regulatory mechanisms, but it is not sufficient to infer that these lncRNAs causally regulate the other adverse genes in this cohort.

**Limitations:**  
Several entries are composite probes, unannotated probes, or genomic loci with uncertain transcript identity. Probe re-annotation, transcript-level quantification, and experimental perturbation are essential before mechanistic interpretation.

---

## 3. Key genes and interaction modules

| Candidate | Current result and likely role | Nature of relationship |
|---|---|---|
| **INHBB** | Strongest adverse association, HR 1.433, FDR 0.0011. Candidate marker of a growth-factor/stromal signaling state. | **Pathway co-membership** with TGF-β-family biology; a direct regulatory relationship with the other listed genes is **not established** by these data. |
| **ITGBL1–DCBLD2–PTPN14–ABL2 module** | All adverse and compatible with matrix sensing, adhesion, and motility. | **Pathway co-membership** and possible **indirect network relationship**. The table does not establish direct physical interaction or transcriptional regulation. |
| **TPM4** | Adverse, HR 1.364; may represent cytoskeletal remodeling and contractile/motility-related state. | Likely **functional co-membership** with adhesion/migration programs; direct physical interactions are not demonstrated here. |
| **NT5E/CD73** | Adverse, HR 1.313; compatible with extracellular adenosine production and immune suppression. | **Enzymatic pathway relationship** with extracellular purine metabolism. A direct interaction with LGALS9 or TAPBPL is not shown. |
| **CDX1–CDX2 module** | Both protective, supporting retained intestinal epithelial identity. | **Regulatory relationship** is biologically plausible because both are intestinal transcription factors, but co-regulation in this cohort is not directly demonstrated. |
| **LGALS4–MYO5B module** | Protective and compatible with differentiated epithelial structure and intestinal function. | **Pathway/tissue-state co-membership**, not a direct physical interaction. |
| **ATP23–NDUFA9–COA3–TIMM13 module** | Protective mitochondrial genes with highly coherent direction. | **Pathway co-membership** in mitochondrial respiratory-chain maintenance; direct protein interactions cannot be inferred from HR concordance. |
| **CS–OGDHL–MCCC2–GLYCTK module** | Protective genes spanning TCA-cycle, amino-acid, and central-carbon metabolism. | **Metabolic pathway co-membership**; no direct gene-gene regulatory relationship established. |
| **MIR31HG–ZEB1-AS1–NR2F1-AS1 module** | Multiple adverse noncoding-RNA features, potentially marking regulatory plasticity or dedifferentiation. | **Co-prognostic module**. Any direct lncRNA-mediated regulation of EMT or matrix genes remains **putative** and requires perturbation evidence. |

The HR values indicate association per unit of the measured expression variable; their clinical comparability may be limited if genes were differently normalized or modeled.

---

## 4. Validation priorities

### 1. Validate an invasive/stromal matrix program  
**Classification:** Mechanistic hypothesis; also a confounding/composition check.

- **Why prioritize:** Multiple adverse genes converge on adhesion, matrix remodeling, and cytoskeletal biology.
- **Current evidence:** Concordant adverse HRs for ITGBL1, DCBLD2, PTPN14, ABL2, TPM4, SCEL, and ADAMTS18.
- **External evidence:** Matrix remodeling and epithelial–mesenchymal plasticity are well-established features of aggressive colorectal cancer, but this does not prove that the present genes form a causal module.
- **Next step:** Calculate an independent EMT/ECM/stromal score; validate by bulk deconvolution and spatial transcriptomics or immunohistochemistry for ITGBL1, DCBLD2, NT5E, fibroblast markers, and tumor epithelial markers.
- **Conclusion level:** **Supported hypothesis**, not established mechanism.

### 2. Test whether the mitochondrial signal reflects tumor-cell metabolic function  
**Classification:** Mechanistic hypothesis and biomarker.

- **Why prioritize:** The protective mitochondrial signal is broad and statistically coherent.
- **Current evidence:** ATP23, NDUFA9, COA3, TIMM13, ATP5B, ATP5G1, CS, OGDHL, MCCC2, and GLYCTK are mostly protective.
- **External evidence:** Oxidative metabolism and mitochondrial state are biologically relevant to colorectal-cancer differentiation and progression, but bulk expression cannot distinguish metabolic activity from mitochondrial abundance or epithelial purity.
- **Next step:** Measure oxygen-consumption rate, mitochondrial mass, ATP production, and TCA-cycle metabolites in organoids or tumor-derived cells; compare with tumor purity and epithelial scores.
- **Conclusion level:** **Supported association**; mechanistic interpretation remains a **supported hypothesis**.

### 3. Determine whether NT5E marks an immunosuppressive adenosine microenvironment  
**Classification:** Biomarker and therapeutic hypothesis.

- **Why prioritize:** NT5E is a significant adverse marker with a plausible immunoregulatory function.
- **Current evidence:** NT5E HR 1.313, FDR 0.0394, in the context of other adverse stromal/growth-factor genes.
- **External evidence:** CD73-mediated extracellular adenosine production is a recognized immunoregulatory mechanism in cancer. However, drug availability or prior literature alone does not establish therapeutic benefit in colorectal cancer.
- **Next step:** Quantify NT5E protein, extracellular adenosine-related metabolites, CD39/ENTPD1, adenosine receptors, immune-cell composition, and response to CD73-axis perturbation in co-culture or organoid–immune models.
- **Conclusion level:** **Supported biomarker hypothesis**; therapeutic relevance is **exploratory**.

### 4. Validate the CDX1/CDX2 differentiation module as an independent prognostic biomarker  
**Classification:** Biomarker.

- **Why prioritize:** Both CDX1 and CDX2 are protective, and their interpretation is reinforced by LGALS4 and MYO5B.
- **Current evidence:** CDX2 HR 0.748 and CDX1 HR 0.781, with additional protective epithelial markers.
- **External evidence:** CDX1/CDX2 are established intestinal-lineage markers and are widely used to characterize colorectal epithelial differentiation. Their prognostic value can vary by molecular subtype and clinical stage.
- **Next step:** Validate protein expression and a composite differentiation score in an independent cohort, adjusted for stage, MSI status, sidedness, treatment, and tumor purity.
- **Conclusion level:** **Established lineage evidence; supported prognostic hypothesis** in this dataset.

### 5. Test whether adverse lncRNAs regulate the invasive state  
**Classification:** Interaction/network hypothesis.

- **Why prioritize:** MIR31HG, ZEB1-AS1, and NR2F1-AS1 show concordant adverse associations, but their mechanistic interpretation is currently uncertain.
- **Current evidence:** Multiple lncRNA-related probes have HRs above 1, including ZEB1-AS1 HR 1.372 and MIR31HG HR 1.309.
- **External evidence:** Individual lncRNAs have been reported in cancer regulatory networks, but literature co-occurrence is not evidence of direct regulation in this cohort.
- **Next step:** Re-annotate probes, quantify full-length transcripts, perform CRISPRi/siRNA perturbation, and measure effects on CDX1/CDX2, ITGBL1, NT5E, migration, and invasion. Use RNA immunoprecipitation or chromatin assays only if a specific regulatory mechanism is proposed.
- **Conclusion level:** **Exploratory hypothesis**.

---

## 5. Major limitations and alternative explanations

1. **Bulk-tissue composition and tumor purity**  
   Adverse ECM and NT5E signals could reflect fibroblasts, endothelial cells, macrophages, or other nonmalignant cells, whereas protective CDX1/CDX2, LGALS4, and MYO5B may reflect higher epithelial tumor content.  
   **Investigation:** ESTIMATE or other purity methods, CIBERSORTx/MuSiC-style deconvolution, epithelial and fibroblast marker scores, and spatial or single-cell validation.

2. **Clinical confounding**  
   OS associations may be driven by stage, metastasis, age, sex, tumor sidedness, MSI status, molecular subtype, or treatment.  
   **Investigation:** Multivariable Cox models and external validation with interaction testing for stage, MSI, sidedness, and treatment.

3. **Association versus causation**  
   HRs identify prognostic correlates; they do not show that any gene causes poor or favorable outcome.  
   **Investigation:** Perturbation experiments, rescue studies, and longitudinal or treatment-response analyses.

4. **Broad and partially overlapping pathway interpretations**  
   ECM, TGF-β, EMT, immune suppression, and dedifferentiation are biologically related and may represent one underlying tumor–stroma axis rather than independent programs. No formal pathway enrichment or gene-set score was provided.  
   **Investigation:** Pre-specified gene-set enrichment, pathway permutation testing, module eigengenes, and evaluation of incremental prognostic value between correlated signatures.

5. **Probe and annotation uncertainty**  
   Several entries are unannotated or composite probe identifiers, and lncRNA probes may not uniquely represent a functional transcript.  
   **Investigation:** Updated probe re-annotation, RNA-seq confirmation, transcript-specific quantification, and exclusion or separate analysis of ambiguous probes.

Overall, the strongest current conclusion is that survival is associated with a contrast between **adverse matrix/stromal and regulatory-state features** and **protective intestinal epithelial and mitochondrial features**. The most clinically actionable next step is not immediate target nomination, but independent validation that these patterns remain prognostic after accounting for stage, molecular subtype, treatment, and tissue composition.
